In a bid to curb the cost of cancer treatment, the Singapore government announced an approved drug list where the most cost-effective drugs can be claimed by the national insurance schemes. Yet, the cost of treatment can spiral - in part thanks to rising insurance premiums. Are people paying too much? How has this new drug list shifted things and should you worry if you don't have insurance? Steven Chia speaks to Associate Professor Ravindran Kanesvaran, chairperson of Singapore Cancer Society's Cancer Treatment Fund Committee, Evelyn Goh deputy CEO and chief advisory officer of Providend and Gina Ho, a 43-year-old general manager and cancer survivor.
See omnystudio.com/listener) for privacy information.
